Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07089901 · ClinicalTrials.gov registry record · Phase 4
Project DEDUCE: Digital Envirotyping to Develop Understanding of Cigarette Smoking and the Environment
A Phase 4 study, sponsored by Duke University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 600
- Enrollment target
NCT07089901 is a Phase 4 study that is actively recruiting participants, run by Duke University. The registered enrollment target is 600 participants.
The verdict
NCT07089901, a Phase 4 study, is actively recruiting participants, sponsored by Duke University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 600 participants
- Enrollment target
Study Summary
Tobacco use is a chronic relapsing condition. That is, even with state-of-the-art treatment, \>70% of smoking cessation attempts end in a return to regular smoking. Research demonstrates that everyday environments associated with smoking trigger craving for cigarettes, provoke smoking, and lead to relapse. However, despite this knowledge, understanding of environmental correlates of smoking has been limited by a reliance on self-report, leading to imprecise information about the physical environments in which people live. To overcome this challenge, the research team has pioneered the development of digital envirotyping, which uses digital tools (e.g., sensors, cameras, artificial intelligence) to efficiently and accurately characterize and categorize environments with the goal of identifying environmental markers of behavior and health. Foundational to the digital envirotyping research is computer vision (CV), a type of artificial intelligence (AI) that enables computer systems to recognize objects and scenes in digital images, mimicking how humans perceive and understand visual information. With CV researchers can extract detailed and accurate information (i.e., objects and location types) about the everyday environments of people who smoke (PWS) and relate that information to smoking behavior. After validating the use of CV, the researchers used CV to develop enviromarkers of relapse risk. Importantly, they identified a novel enviromarker in which people at greater risk for relapse when they quit are exposed to a more consistent level of environment-related smoking risk as they move between their smoking and nonsmoking environments. Research is now needed to advance digital envirotyping and enviromarker development in the field of tobacco addiction. The study will recruit a diverse, national sample of n=500 adults who are interested in quitting smoking. For two weeks prior to quitting, they will undergo photoEMA in which they will take two pictures of their curr
Interventions
- DRUG transdermal nicotine replacement therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2026-05-06 |
| Est. Completion | 2030-03-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07089901
The ClinicalTrials.gov registry entry for NCT07089901 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which transdermal nicotine replacement therapy is the first listed.
NCT07089901 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07089901 about?
NCT07089901 is a clinical study titled "Project DEDUCE: Digital Envirotyping to Develop Understanding of Cigarette Smoking and the Environment". Tobacco use is a chronic relapsing condition. That is, even with state-of-the-art treatment, \>70% of smoking cessation attempts end in a return to regular smoking. Research demonstrates that everyday environments associated with smoking trigger craving for cigarettes, provoke smoking, and lead to r...
What is the current status of trial NCT07089901?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 600 participants. The study started on 2026-05-06. Estimated completion is 2030-03-31.
What interventions are being tested in trial NCT07089901?
The interventions under investigation include: transdermal nicotine replacement therapy (DRUG).
Who is sponsoring clinical trial NCT07089901?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.